These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 2189281)

  • 21. Norgestimate: a clinical overview of a new progestin.
    Bringer J
    Am J Obstet Gynecol; 1992 Jun; 166(6 Pt 2):1969-77. PubMed ID: 1605287
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and clinical profile of a new oral contraceptive containing norgestimate. U.S. clinical trials.
    Corson SL
    Acta Obstet Gynecol Scand Suppl; 1990; 152():25-31. PubMed ID: 2189282
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ovarian activity during regular oral contraceptive use.
    Crosignani PG; Testa G; Vegetti W; Parazzini F
    Contraception; 1996 Nov; 54(5):271-3. PubMed ID: 8934059
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The affinity of norgestimate for uterine progestogen receptors and its direct action on the uterus.
    Killinger J; Hahn DW; Phillips A; Hetyei NS; McGuire JL
    Contraception; 1985 Sep; 32(3):311-9. PubMed ID: 3936677
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of deliberate omission of Trinordiol or Microgynon on the hypothalamo-pituitary-ovarian axis.
    Smith SK; Kirkman RJ; Arce BB; McNeilly AS; Loudon NB; Baird DT
    Contraception; 1986 Nov; 34(5):513-22. PubMed ID: 3102162
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Thirty years after the appearance of the first oral contraceptive, clinical and biological analysis of a new estrogen-progestin combination, a three phase pill containing gestodene].
    Belaisch J; Hommais-loufrani B
    Fertil Contracept Sex; 1988 Apr; 16(4 Suppl):1-8. PubMed ID: 12342078
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins.
    Wiegratz I; Jung-Hoffmann C; Kuhl H
    Contraception; 1995 Jun; 51(6):341-6. PubMed ID: 7554973
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolic changes during treatment with two different progestogens.
    Refn H; Kjaer A; Lebech AM; Borggaard B; Schierup L; Bremmelgaard A
    Am J Obstet Gynecol; 1990 Jul; 163(1 Pt 2):374-7. PubMed ID: 2115298
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of two oral contraceptives containing ethinyl estradiol and gestodene or norgestimate on different lipid and lipoprotein parameters.
    Wiegratz I; Jung-Hoffmann C; Gross W; Kuhl H
    Contraception; 1998 Aug; 58(2):83-91. PubMed ID: 9773262
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of ovulation by progestin analogs (agonists vs antagonists): preliminary evidence for different sites and mechanisms of actions.
    Heikinheimo O; Gordon K; Williams RF; Hodgen GD
    Contraception; 1996 Jan; 53(1):55-64. PubMed ID: 8631191
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The new era in oral contraception: pills containing gestodene, norgestimate, and desogestrel.
    London RS
    Obstet Gynecol Surv; 1992 Nov; 47(11):777-82. PubMed ID: 1436906
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Binding of a contraceptive progestogen ORG 2969 and its metabolites to receptor proteins and human sex hormone binding globulin.
    Bergink EW; Hamburger AD; de Jager E; van der Vies J
    J Steroid Biochem; 1981 Feb; 14(2):175-83. PubMed ID: 6451769
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of the progestogens, gestodene, 3-keto desogestrel, levonorgestrel, norethisterone and norgestimate on the oxidation of ethinyloestradiol and other substrates by human liver microsomes.
    Back DJ; Houlgrave R; Tjia JF; Ward S; Orme ML
    J Steroid Biochem Mol Biol; 1991 Feb; 38(2):219-25. PubMed ID: 2004043
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Receptor binding of norgestimate--a new orally active synthetic progestational compound.
    Juchem M; Pollow K; Elger W; Hoffmann G; Möbus V
    Contraception; 1993 Mar; 47(3):283-94. PubMed ID: 8384965
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Binding of oral contraceptive progestogens to serum proteins and cytoplasmic receptor.
    Juchem M; Pollow K
    Am J Obstet Gynecol; 1990 Dec; 163(6 Pt 2):2171-83. PubMed ID: 2175153
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma hormone levels in women receiving new oral contraceptives containing ethinyl estradiol plus levonorgestrel or desogestrel.
    Gaspard UJ; Romus MA; Gillain D; Duvivier J; Demey-Ponsart E; Franchimont P
    Contraception; 1983 Jun; 27(6):577-90. PubMed ID: 6225622
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical evidence of the minimal androgenic activity of norgestimate.
    Chapdelaine A; Desmarais JL; Derman RJ
    Int J Fertil; 1989; 34(5):347-52. PubMed ID: 2571595
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New progestogens in oral contraceptives.
    Runnebaum B; Rabe T
    Am J Obstet Gynecol; 1987 Oct; 157(4 Pt 2):1059-63. PubMed ID: 2960242
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum pharmacokinetics of orally administered desogestrel and binding of contraceptive progestogens to sex hormone-binding globulin.
    Bergink W; Assendorp R; Kloosterboer L; van Lier W; Voortman G; Qvist I
    Am J Obstet Gynecol; 1990 Dec; 163(6 Pt 2):2132-7. PubMed ID: 2147817
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Progesterone-Progestin receptors.
    Raynaud JP; Philibert D; Azadian-Boulanger G
    Basic Life Sci; 1974; 4(PART A):143-60. PubMed ID: 4374925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.